RecruitingNot Applicable

EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

Italy500 participantsStarted 2023-01-01

Plain-language summary

The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Age between 18 and 75 years;
✓. Males and females;
✓. Willingness to sign the informed consent;
✓. High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
✓. Chronic migraine, according to the ICHD-III criteria;

Change from baseline in monthly migraine days (MMD) in HFEM or monthly headache days (MHD) in CM;

Timeframe: over 12 weeks of treatment compared to baseline

Change from baseline in MMD in HFEM or MHD in CM;

Timeframe: over 24 weeks of treatment compared to baseline

Change from baseline in MMD in HFEM or MHD in CM;

Timeframe: over 48 weeks of treatment compared to baseline

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

Timeframe: over 12 months of treatment compared to baseline

NCT IDNCT05570149

SponsorIRCCS San Raffaele Roma

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-31

Piero Barbanti, MD, PhD